Leah Christl, PhD, associate director for therapeutic biologics, director of the therapeutic biologics and biosimilars staff in the office of new drugs in the FDA’s Center for Drug Evaluation and Research reviewed the status of some of the planned deliverables for the 4 major elements of the Biosimilar Action Plan during the fifth DIA Biosimilars Conference, held October 22 to 23, 2018, in London, United Kingdom.